120 related articles for article (PubMed ID: 36434616)
1. PI3K/AKT signaling allows for MAPK/ERK pathway independency mediating dedifferentiation-driven treatment resistance in melanoma.
Corrales E; Levit-Zerdoun E; Metzger P; Mertes R; Lehmann A; Münch J; Lemke S; Kowar S; Boerries M
Cell Commun Signal; 2022 Nov; 20(1):187. PubMed ID: 36434616
[TBL] [Abstract][Full Text] [Related]
2. Quantitative Proteomics Links the Intermediate Filament Nestin to Resistance to Targeted BRAF Inhibition in Melanoma Cells.
Schmitt M; Sinnberg T; Nalpas NC; Maass A; Schittek B; Macek B
Mol Cell Proteomics; 2019 Jun; 18(6):1096-1109. PubMed ID: 30890564
[TBL] [Abstract][Full Text] [Related]
3. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
[TBL] [Abstract][Full Text] [Related]
4. CD133-Dependent Activation of Phosphoinositide 3-Kinase /AKT/Mammalian Target of Rapamycin Signaling in Melanoma Progression and Drug Resistance.
Kharouf N; Flanagan TW; Alamodi AA; Al Hmada Y; Hassan SY; Shalaby H; Santourlidis S; Hassan SL; Haikel Y; Megahed M; Brodell RT; Hassan M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334632
[TBL] [Abstract][Full Text] [Related]
5. ALDH1A1 confers resistance to RAF/MEK inhibitors in melanoma cells by maintaining stemness phenotype and activating PI3K/AKT signaling.
Ciccone V; Simonis V; Del Gaudio C; Cucini C; Ziche M; Morbidelli L; Donnini S
Biochem Pharmacol; 2024 May; 224():116252. PubMed ID: 38701866
[TBL] [Abstract][Full Text] [Related]
6. COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors.
Xie Y; Cao Z; Wong EW; Guan Y; Ma W; Zhang JQ; Walczak EG; Murphy D; Ran L; Sirota I; Wang S; Shukla S; Gao D; Knott SR; Chang K; Leu J; Wongvipat J; Antonescu CR; Hannon G; Chi P; Chen Y
J Clin Invest; 2018 Apr; 128(4):1442-1457. PubMed ID: 29360641
[TBL] [Abstract][Full Text] [Related]
7. Evodiamine inhibits growth of vemurafenib drug-resistant melanoma via suppressing IRS4/PI3K/AKT signaling pathway.
Guo X; Huang S; Zhang Y; Wang H; Li L; Ran J; Chen D; Li X; Li J
J Nat Med; 2024 Mar; 78(2):342-354. PubMed ID: 38324123
[TBL] [Abstract][Full Text] [Related]
8. Cooperative function of oncogenic MAPK signaling and the loss of Pten for melanoma migration through the formation of lamellipodia.
Yasuta Y; Kaminaka R; Nagai S; Mouri S; Ishida K; Tanaka A; Zhou Y; Sakurai H; Yokoyama S
Sci Rep; 2024 Jan; 14(1):1525. PubMed ID: 38233537
[TBL] [Abstract][Full Text] [Related]
9. Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts.
Corrales E; Levit-Zerdoun E; Metzger P; Kowar S; Ku M; Brummer T; Boerries M
Cell Commun Signal; 2021 Dec; 19(1):123. PubMed ID: 34930313
[TBL] [Abstract][Full Text] [Related]
10. Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study.
Pópulo H; Domingues B; Sampaio C; Lopes JM; Soares P
J Exp Pharmacol; 2021; 13():521-535. PubMed ID: 34079392
[TBL] [Abstract][Full Text] [Related]
11. Combined PI3K and MAPK inhibition synergizes to suppress PDAC.
Bye BA; Jack J; Pierce A; Walsh RM; Eades A; Chalise P; Olou A; VanSaun MN
bioRxiv; 2023 Aug; ():. PubMed ID: 37645960
[TBL] [Abstract][Full Text] [Related]
12. MiR126-targeted-nanoparticles combined with PI3K/AKT inhibitor as a new strategy to overcome melanoma resistance.
Arasi MB; De Luca G; Chronopoulou L; Pedini F; Petrucci E; Flego M; Stringaro A; Colone M; Pasquini L; Spada M; Lulli V; Perrotta MC; Calin GA; Palocci C; Biffoni M; Felicetti F; Felli N
Mol Ther; 2024 Jan; 32(1):152-167. PubMed ID: 37990493
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma.
Irvine M; Stewart A; Pedersen B; Boyd S; Kefford R; Rizos H
Oncogenesis; 2018 Sep; 7(9):72. PubMed ID: 30237495
[TBL] [Abstract][Full Text] [Related]
14. The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.
Krayem M; Sabbah M; Najem A; Wouters A; Lardon F; Simon S; Sales F; Journe F; Awada A; Ghanem GE; Van Gestel D
Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31374895
[TBL] [Abstract][Full Text] [Related]
15. Chitinase-3 like-protein-1 (YKL-40) Promotes Anorectal Mucosal Melanoma Progression via the PI3K-AKT Signaling Pathway.
Li C; Wang Y; Ren X; Li Y
Altern Ther Health Med; 2023 Dec; ():. PubMed ID: 38295313
[TBL] [Abstract][Full Text] [Related]
16. The Complexity of the ERK/MAP-Kinase Pathway and the Treatment of Melanoma Skin Cancer.
Wellbrock C; Arozarena I
Front Cell Dev Biol; 2016; 4():33. PubMed ID: 27200346
[TBL] [Abstract][Full Text] [Related]
17. Glutamatergic Signaling a Therapeutic Vulnerability in Melanoma.
Eddy K; Chen S
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359771
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.
Al Hmada Y; Brodell RT; Kharouf N; Flanagan TW; Alamodi AA; Hassan SY; Shalaby H; Hassan SL; Haikel Y; Megahed M; Santourlidis S; Hassan M
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38275910
[TBL] [Abstract][Full Text] [Related]
19. Dermokine mutations contribute to epithelial-mesenchymal transition and advanced melanoma through ERK/MAPK pathways.
Ma W; Wu Z; Maghsoudloo M; Ijaz I; Dehghan Shasaltaneh M; Zhang Y; Weng Q; Fu J; Imani S; Wen QL
PLoS One; 2023; 18(7):e0285806. PubMed ID: 37432950
[TBL] [Abstract][Full Text] [Related]
20. Src-mediated regulation of the PI3K pathway in advanced papillary and anaplastic thyroid cancer.
Beadnell TC; Nassar KW; Rose MM; Clark EG; Danysh BP; Hofmann MC; Pozdeyev N; Schweppe RE
Oncogenesis; 2018 Feb; 7(2):23. PubMed ID: 29487290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
